A Phase IIa proof-of-concept study of RX-0201 (Archexin®) for the treatment of hepatocellular carcinoma (HCC)

Trial Profile

A Phase IIa proof-of-concept study of RX-0201 (Archexin®) for the treatment of hepatocellular carcinoma (HCC)

Planning
Phase of Trial: Phase II

Latest Information Update: 14 Feb 2018

At a glance

  • Drugs RX 0201 (Primary)
  • Indications Liver cancer
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 14 Feb 2018 New trial record
    • 08 Feb 2018 According to a Rexahn Pharmaceuticals media release, Zhejiang Haichang Biotechnology will fund this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top